Scholarlink

Purpose of Review <p>To investigate the role of short-chain fatty acids (SCFAs) in the pathogenesis of osteoporosis and their potential value as therapeutic targets.</p> Recent Findings <p>Recent studies have shown that SCFAs, metabolic products of gut microbiota, play a crucial regulatory role in bone remodeling. SCFAs achieve this by activating G protein-coupled receptors (GPCRs), inhibiting histone deacetylases (HDACs), and regulating signaling pathways involved in bone metabolism. This effectively suppresses osteoclast activity, reduces bone resorption, enhances osteoblast function, and alleviates oxidative stress, thereby promoting bone formation. These findings not only reveal the key mechanisms by which SCFAs maintain bone metabolic homeostasis but also highlight their potential for treating osteoporosis in the elderly and postmenopausal women. Related clinical trials and drug research are currently underway.</p> Summary <p> This review explores the potential value and theoretical basis of targeting SCFAs for the prevention and treatment of osteoporosis, summarizes existing clinical trials and related drug research, and provides new directions for developing future treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of Short-Chain Fatty Acids and Derived Metabolites in Osteoporosis

  • 期刊论文

  • 发表日期：

    2026年7月24日

查看全文
  • Guanghong Qiu,
  • Sihui Xie,
  • Wenjia Luo,
  • Kangping Yang,
  • Jiaqiang Wu,
  • Xianhuan Zhou,
  • Shiqi Li,
  • Yufan Hu,
  • Liang Yang

摘要

Purpose of Review

To investigate the role of short-chain fatty acids (SCFAs) in the pathogenesis of osteoporosis and their potential value as therapeutic targets.

Recent Findings

Recent studies have shown that SCFAs, metabolic products of gut microbiota, play a crucial regulatory role in bone remodeling. SCFAs achieve this by activating G protein-coupled receptors (GPCRs), inhibiting histone deacetylases (HDACs), and regulating signaling pathways involved in bone metabolism. This effectively suppresses osteoclast activity, reduces bone resorption, enhances osteoblast function, and alleviates oxidative stress, thereby promoting bone formation. These findings not only reveal the key mechanisms by which SCFAs maintain bone metabolic homeostasis but also highlight their potential for treating osteoporosis in the elderly and postmenopausal women. Related clinical trials and drug research are currently underway.

Summary

This review explores the potential value and theoretical basis of targeting SCFAs for the prevention and treatment of osteoporosis, summarizes existing clinical trials and related drug research, and provides new directions for developing future treatment strategies.